Table 1 The clinicopathological characteristics of OC patients
From: Investigating PPT2’s role in ovarian cancer prognosis and immunotherapy outcomes
Characters | Histology/Stage | Patients (n) | Median | Percentage/Range |
|---|---|---|---|---|
Age | 45 | 57.5 years | 24–77 years | |
Histology | Serous | 27 | 60.0% | |
Endometrioid | 10 | 22.2% | ||
Clear cell | 4 | 8.9% | ||
Mixed type | 4 | 8.9% | ||
FIGO stage | I-II | 10 | 22.2% | |
III- IV | 35 | 77.8% | ||
Histological grade | G1 | 9 | 20.0% | |
G2 | 11 | 24.4% | ||
G3 | 25 | 55.6% | ||
Tumor residual size | 0 cm | 17 | 37.8% | |
≤ 1 cm | 21 | 46.7% | ||
> 1 cm | 7 | 15.5% | ||
Follow-up time | 45 | 27 months | 14–36 months |